Extended IGF-1 analogue with reduced binding-protein affinity
PRODUCT PROFILE
IGF-1 LR3
£47.99
IGF-1 LR3 is extended igf-1 analogue with reduced binding-protein affinity. Researchers examine it in relation to sustained igf-1 receptor signalling in growth, metabolism and cell-culture models.
Why it is distinct
Designed for longer, less binding-protein-restricted IGF signalling than native IGF-1 or IGF-1 DES.
- Evidence stageExperimental
- AvailabilityAvailable · 10 in stock
- Batch recordPublished after verification
- DispatchConfirmed at checkout
10 in stock
PRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
IGF-1 LR3 is extended igf-1 analogue with reduced binding-protein affinity. Researchers examine it in relation to sustained igf-1 receptor signalling in growth, metabolism and cell-culture models.
Research focus+
Researchers study how prolonged IGF-1 signalling affects cell growth, metabolism and survival. Because it strongly affects growth pathways, it is not presented as a wellness or personal-use product.
How the mechanism differs+
Sequence extension and substitution reduce IGF-binding-protein interaction, increasing free analogue exposure in experimental systems.
Evidence and limitations+
Experimental laboratory reagent without an authorised human indication; safety and efficacy are not established.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers study how prolonged IGF-1 signalling affects cell growth, metabolism and survival. Because it strongly affects growth pathways, it is not presented as a wellness or personal-use product.
Sequence extension and substitution reduce IGF-binding-protein interaction, increasing free analogue exposure in experimental systems.
Designed for longer, less binding-protein-restricted IGF signalling than native IGF-1 or IGF-1 DES.
Experimental laboratory reagent without an authorised human indication; safety and efficacy are not established.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Experimental
Follistatin 344
£76.001 mgBatch file pendingA ligand-binding inhibitor of the activin/myostatin system, not a GH or IGF secretagogue.
UnavailableAsk about availability -
Early human evidence
CJC-1295 No DAC
Price range: £25.99 through £32.995 mgBatch file pendingShort-duration GHRH signalling, in contrast with albumin-bound, long-acting CJC-1295 DAC.
UnavailableAsk about availability This product has multiple variants. The options may be chosen on the product page -
Established
Sermorelin
£49.005 mgBatch file pendingClosest to the natural active GHRH sequence and shorter acting than tesamorelin or CJC-1295 DAC.
UnavailableAsk about availability -
Early human evidence
Hexarelin
£51.005 mgBatch file pendingA potent older GHRP with less hormonal selectivity than ipamorelin.
UnavailableAsk about availability